Filter News
Area of Research
- (-) Computational Biology (1)
- (-) Fusion and Fission (2)
- Advanced Manufacturing (1)
- Biology and Environment (13)
- Clean Energy (13)
- Computational Engineering (1)
- Computer Science (6)
- Electricity and Smart Grid (1)
- Fuel Cycle Science and Technology (1)
- Functional Materials for Energy (1)
- Isotopes (1)
- Materials (40)
- Materials for Computing (1)
- National Security (42)
- Neutron Science (17)
- Nuclear Science and Technology (2)
- Quantum information Science (1)
- Supercomputing (49)
News Type
News Topics
- (-) Artificial Intelligence (2)
- (-) Physics (1)
- 3-D Printing/Advanced Manufacturing (3)
- Advanced Reactors (6)
- Bioenergy (1)
- Biology (3)
- Biomedical (3)
- Buildings (1)
- Chemical Sciences (4)
- Composites (1)
- Computer Science (3)
- Coronavirus (1)
- Critical Materials (1)
- Decarbonization (2)
- Energy Storage (4)
- Environment (2)
- Exascale Computing (1)
- Fossil Energy (1)
- Frontier (1)
- Fusion (22)
- Grid (2)
- High-Performance Computing (4)
- Isotopes (1)
- ITER (6)
- Materials (1)
- Materials Science (4)
- Microscopy (1)
- Nanotechnology (1)
- Net Zero (1)
- Neutron Science (2)
- Nuclear Energy (26)
- Partnerships (3)
- Security (2)
- Simulation (3)
- Space Exploration (1)
- Summit (1)
- Sustainable Energy (4)
- Transportation (2)
Media Contacts
ORNL hosted its fourth Artificial Intelligence for Robust Engineering and Science, or AIRES, workshop from April 18-20. Over 100 attendees from government, academia and industry convened to identify research challenges and investment areas, carving the future of the discipline.
Oak Ridge National Laboratory physicist Elizabeth “Libby” Johnson (1921-1996), one of the world’s first nuclear reactor operators, standardized the field of criticality safety with peers from ORNL and Los Alamos National Laboratory.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.